XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2023
Disclosure Text Block [Abstract]  
Fair Value Measurements
2.
Fair Value Measurements

The Company uses various valuation approaches in determining the fair value of its assets and liabilities. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in

pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1 -

Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access

Level 2 -

Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities

Level 3 -

Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement.

Cash, Cash Equivalents and Marketable Securities Held to Maturity

The following table summarizes the Company's cash, cash equivalents and marketable securities held to maturity as of June 30, 2023 and December 31, 2022 (amounts in thousands):

 

 

As of June 30, 2023

 

 

 

Amortized
 Costs

 

 

Gross
Unrealized
Gains

 

 

Gross
Unrealized
Losses

 

 

Estimated
Fair Value

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Cash and money market funds

 

$

603,656

 

 

$

 

 

$

 

 

$

603,656

 

Total cash and cash equivalents

 

$

603,656

 

 

$

 

 

$

 

 

$

603,656

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2022

 

 

 

Amortized
Cost

 

 

Gross
Unrealized
Gains

 

 

Gross
Unrealized
Losses

 

 

Estimated
Fair Value

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Cash and money market funds

 

$

523,458

 

 

$

 

 

$

 

 

$

523,458

 

Total cash and cash equivalents

 

 

523,458

 

 

 

 

 

 

 

 

 

523,458

 

Marketable securities held to maturity:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills - short-term

 

 

100,299

 

 

 

24

 

 

 

 

 

 

100,323

 

Total cash, cash equivalents and marketable securities

 

$

623,757

 

 

$

24

 

 

$

 

 

$

623,781

 

 

 

 

 

 

 

 

 

 

 

 

 

 

During the fourth quarter of 2022, the Company purchased $100.0 million of 6-month U.S. treasury bills with the positive intent and ability to hold them until maturity. Therefore, the Company classified this investment as held to maturity and stated it at amortized cost on the condensed consolidated balance sheet. These U.S. treasury bills matured in June 2023. The amortized cost and the fair value of the Company's held to maturity securities by contractual maturity at December 31, 2022 is summarized below:

 

 

 

December 31, 2022

 

 

 

 

Amortized
 Costs

 

 

Estimated
Fair Value

 

 

Maturity of one year or less

 

$

100,299

 

 

$

100,323

 

 

Total

 

$

100,299

 

 

$

100,323

 

 

 

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of June 30, 2023 and December 31, 2022 (amounts in thousands):

 

 

 

As of June 30, 2023

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market accounts

 

$

433,966

 

 

$

 

 

$

 

 

$

433,966

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Short-term contingent consideration

 

$

 

 

$

 

 

$

16,363

 

 

$

16,363

 

Long-term contingent consideration

 

$

 

 

$

 

 

$

44,277

 

 

$

44,277

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2022

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market accounts

 

$

343,929

 

 

$

 

 

$

 

 

$

343,929

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Short-term contingent consideration

 

$

 

 

$

 

 

$

13,950

 

 

$

13,950

 

Long-term contingent consideration

 

$

 

 

$

 

 

$

51,559

 

 

$

51,559

 

Contingent Consideration – Earnouts

As of June 30, 2023, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay in connection with the completed acquisitions of Avitide in September 2021 and FlexBiosys in April 2023, was $125.0 million over a three-year earnout period and $42.0 million over a two-year earnout period, respectively. Refer to Note 4, "Acquisitions" included in Part II, Item 8, “Financial Statements and Supplementary Data” to our Form 10-K and Note 3, "Acquisition of FlexBiosys, Inc.," to this report for additional information on the contingent consideration earnouts.

During 2023, a change in market inputs used to calculate the discount rate resulted in an increase in amounts reported as of June 30, 2023. A reconciliation of the change in the fair value of contingent consideration - earnouts is included in the following table (amounts in thousands):

 

Balance at December 31, 2022

 

$

65,509

 

Acquisition date fair value of contingent consideration earnout

 

 

6,632

 

Payment of contingent consideration earnout

 

 

(14,527

)

Decrease in fair value of contingent consideration earnouts

 

 

3,026

 

Balance at June 30, 2023

 

$

60,640

 

 

The recurring Level 3 fair value measurement of our contingent consideration earnout that we expect to be required to settle our 2023, 2024 and 2025 contingent consideration obligations for Avitide and FlexBiosys include the following significant unobservable inputs (amounts in thousands, except percent data):

 

Contingent Consideration Earnout

 

Fair Value as of
 June 30, 2023

 

 

Valuation Technique

 

Unobservable Input

 

Range

 

Weighted Average(1)

 

 

 

 

 

 

 

 

Probability of

 

 

 

 

 

 

 

 

 

 

 

 

Success

 

100%

 

100%

Commercialization-based payments

 

$

 

19,175

 

 

Monte Carlo
Simulation

 

Earnout Discount Rate

 

6.1%-6.4%

 

6.3%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Volatility

 

22.5%-24.6%

 

23.6%

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue and Volume-
based payments

 

$

 

35,960

 

 

Monte Carlo
Simulation

 

Revenue & Volume
Discount Rate

 

5.7%-9.3%

 

7.5%

 

 

 

 

 

 

 

 

Earnout Discount Rate

 

6.1%-6.4%

 

6.3%

 

 

 

 

 

 

 

 

Probability of
 Success

 

100%

 

100%

Manufacturing line expansions

 

$

 

5,505

 

 

Probability-weighted present value

 

Earnout Discount Rate

 

6.1%-6.4%

 

6.3%

 

(1)
Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.

Fair Value Measured on a Nonrecurring Basis

During the three and six months ended June 30, 2023, there were no re-measurements to the fair value of financial assets and liabilities that are measured at fair value on a nonrecurring basis.